BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36715448)

  • 21. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
    Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
    PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide combinatorial libraries identify TSC2 as a death-associated protein kinase (DAPK) death domain-binding protein and reveal a stimulatory role for DAPK in mTORC1 signaling.
    Stevens C; Lin Y; Harrison B; Burch L; Ridgway RA; Sansom O; Hupp T
    J Biol Chem; 2009 Jan; 284(1):334-344. PubMed ID: 18974095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
    Fuchs A; König K; Heukamp LC; Fassunke J; Kirfel J; Huss S; Becker AJ; Büttner R; Majores M
    Diagn Pathol; 2014 Mar; 9():48. PubMed ID: 24593867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
    Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
    eNeuro; 2015; 2(6):. PubMed ID: 26693177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
    Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
    Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
    Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
    Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
    Ma L; Chen Z; Erdjument-Bromage H; Tempst P; Pandolfi PP
    Cell; 2005 Apr; 121(2):179-93. PubMed ID: 15851026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
    Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
    PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
    Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
    Gan B; Yoo Y; Guan JL
    J Biol Chem; 2006 Dec; 281(49):37321-9. PubMed ID: 17043358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.
    Lopez-Rivera E; Jayaraman P; Parikh F; Davies MA; Ekmekcioglu S; Izadmehr S; Milton DR; Chipuk JE; Grimm EA; Estrada Y; Aguirre-Ghiso J; Sikora AG
    Cancer Res; 2014 Feb; 74(4):1067-78. PubMed ID: 24398473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
    Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
    Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of the Tuberous Sclerosis Complex 2 (TSC2) N Terminus Provides Insight into Complex Assembly and Tuberous Sclerosis Pathogenesis.
    Zech R; Kiontke S; Mueller U; Oeckinghaus A; Kümmel D
    J Biol Chem; 2016 Sep; 291(38):20008-20. PubMed ID: 27493206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.
    Dere R; Wilson PD; Sandford RN; Walker CL
    PLoS One; 2010 Feb; 5(2):e9239. PubMed ID: 20169078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
    Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
    Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
    Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
    Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
    Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
    Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.